Compare Sea Limited (SE) vs TG Therapeutics Inc (TGTX) Price & Performance

SE stock trades at $129.71, up 12.99% on strong Q2 2026 results, with revenue of $7.8 billion (up 48% year-over-year) and net income of $458 million (up 11%). The technical picture is bullish with moving averages supporting the uptrend, though RSI levels indicate overbought conditions. Fundamentals show robust revenue growth and improving profitability, with net income margin reaching 6.36% in 2025. Analyst sentiment remains positive with a consensus buy rating and $128.33 price target.

The outlook for SE is favorable given accelerating growth across e-commerce, fintech, and gaming segments, but risks include margin pressure from increased investments and credit costs. The stock's high valuation multiples (P/E of 50.78) require sustained execution to justify further gains. Near-term resistance lies at $133, with support at $128.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.